Barrington Research Reiterates AtriCure
Barrington Reserach reiterated its AtriCure (NASDAQ: ATRC) Outperform rating in a research report published today. Barrington Research has a $17 price target on AtriCure.
In the report, Barrington Research stated, "We are reiterating our OUTPERFORM rating given our belief that ATRC's hybrid ablation procedure will be the standard of care procedure for the less invasive surgical management of persistent and permanent AF and that ATRC's LAA clip will become standard of care for the epicardial treatment of the LAA."
Shares of AtriCure closed today at $10.71, up 3.48% from Monday's market close.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.